Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 60 Neoplasms 7 Neoplasm Metastasis 6 Melanoma 5 Carcinoma, Non-Small-Cell Lung 5 Neoplasms by Site 4 Colorectal Neoplasms 4 Breast Diseases 4 Ovarian Neoplasms 3 Hereditary Sensory and Autonomic Neuropathies 3 Endometrial Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Neuroblastoma 2 Multiple Endocrine Neoplasia Type 1 2 Lymphoma 2 Lung Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Teratoma 1 Stomach Neoplasms 1 Solid Tumors Harboring a BRAF V600 Mutation 1 Solid Tumors 1 Rhabdomyosarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Osteitis Deformans 1 Neoplasms, Germ Cell and Embryonal 1

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × HR+/HER2- Breast Cancer × ribociclib × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡